MEDIA RELEASE

# Torrent Pharma announces Q3 FY26 results

Robust branded business performance drives net profit growth of 26%; acquisition of 48.8% stake in JB Chemicals & Pharma completed

**Ahmedabad, 13th February 2026:** Torrent Pharmaceuticals Limited (''Company") today announced its financial results for the third quarter of FY 26.

## Key Highlights for Q3 FY26:

- Revenue at Rs. 3,303 crores, up by 18% YoY
- Op. EBITDA* at Rs.1,088 crores, up by 19% YoY
- Op. EBITDA margin* at 33%; Gross Margin: 76%
- Net Profit after tax at Rs. 635 crores, up by 26% YoY

**Performance summary:**

| Results | Q3 FY26 | | Q3 FY25 | | YoY % | 9M FY26 | | 9M FY25 | | YoY % |
|---|---|---|---|---|---|---|---|---|---|---|
| | Rs cr | % | Rs cr | % | | Rs cr | % | Rs cr | % | |
| Revenues | 3,303 | | 2,809 | | 18% | 9,783 | | 8,557 | | 14% |
| Gross profit | 2,504 | 76% | 2,136 | 76% | 17% | 7,410 | 76% | 6,512 | 76% | 14% |
| Op EBITDA* | 1,088 | 33% | 914 | 33% | 19% | 3,203 | 33% | 2,757 | 32% | 16% |
| Exceptional item** | (10) | 0% | - | - | - | (23) | 0% | - | - | - |
| PAT | 635 | 19% | 503 | 18% | 26% | 1,774 | 18% | 1,413 | 17% | 26% |
| R&D spend | 154 | 5% | 151 | 5% | 2% | 468 | 5% | 431 | 5% | 9% |

**Before exceptional items*

*** Exceptional item comprises regulatory & statutory filing fees and other related costs associated with acquisition of J.B. Chemicals & Pharmaceuticals Ltd.*



TORRENT PHARMACEUTICALS LIMITED
CIN : L24230GJ1972PLC002126
Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

**India:**

- India revenues at Rs 1,798 crores were up 14%
- As per AIOCD PharmaTrac secondary market data, IPM growth for the quarter was 10%.
- Continued volume outperformance over IPM in chronic and sub-chronic therapies led by Cardiac, Gastro, and Diabetes (OAD) segments
- For 9M FY26, revenues were Rs 5,430 crores, up by 12%.

**Brazil:**

- Brazil revenues at Rs 371 crores, were up by 27%.
- Constant currency revenues, at R$ 224 million, were up by 10%.
- As per IQVIA, Torrent grew at 13% vs market growth of 7%; growth was aided by the performance of top brands & recent launches.
- Torrent has 60 products under ANVISA review.
- For 9M FY26, revenues were Rs 907 crores, up by 21% (Constant currency revenue: R$ 564 million, up by 13%).

**United States:**

- US business revenues at Rs 321 crores, were up by 19%.
- Constant currency revenues at $36 million, were up by 12% compared to the same period in the previous year. Recent launches have achieved target market shares.
- For 9M FY26, revenues were Rs 967 crores, up by 21% (Constant currency revenue: $111 million up by 16%).

**Germany:**

- Germany revenues at Rs 304 crores, were up by 8%.
- Constant currency revenues at EUR 29 million, were down by 6%.
- Growth continued to be impacted due to supply disruption at a third party supplier.
- For 9M FY26, revenues were Rs 916 crores, up by 7% (Constant currency revenue: EUR 91 million, down by 3%).



TORRENT PHARMACEUTICALS LIMITED
CIN : L24230GJ1972PLC002126
Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

TORRENT PHARMA

**About Torrent Pharmaceuticals Ltd:**

Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. Post JB Pharma acquisition it is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Cosmo-Dermatology.

It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.



TORRENT PHARMACEUTICALS LIMITED
CIN : L24230GJ1972PLC002126
Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com